Loading clinical trials...
Loading clinical trials...
A Randomized Patient-and-physician Blinded, Placebo-controlled, 24-week Study to Assess the Safety, Tolerability and Efficacy of LMB763 in Patients With Diabetic Nephropathy
Conditions
Interventions
Nidufexor
Placebo
+1 more
Locations
18
United States
Novartis Investigative Site
Miami Lakes, Florida, United States
Novartis Investigative Site
Albany, New York, United States
Novartis Investigative Site
Norman, Oklahoma, United States
Novartis Investigative Site
El Paso, Texas, United States
Novartis Investigative Site
Sugar Land, Texas, United States
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Start Date
December 17, 2018
Primary Completion Date
May 3, 2021
Completion Date
May 3, 2021
Last Updated
August 10, 2022
NCT01802034
NCT06661174
NCT04931537
NCT06954090
NCT07476248
NCT06072326
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions